Sepsis Leaves a Readable Trail. Two Studies Show Where to Look for It.

A blood signal tied to outcome

In a preprint, researchers assessed fibrinolysis resistance in sepsis using the TPA-LT/FIBA10 measure and found it associated with increased PAI-1 and decreased plasminogen levels in septic patients. Patients with a fibrinolysis inhibitor-high, substrate-depleted profile had 61% intensive care mortality, compared with 29% in the preserved-fibrinolysis group. PAI-1 levels fell within 72 hours in sepsis survivors but remained unchanged in non-survivors. The pattern is consistent: the patients whose clot breakdown stayed blocked were the patients who fared worst, and the signal moved over time in survivors while staying flat in those who died. m:…1252

A companion preprint modelling the same problem found fibrinolysis resistance to be a significant predictor of 28-day mortality in intensive care sepsis patients, with each e-fold increase in TPA-LT/FIBA10 associated with a 2.2-fold increase in odds of death. In laboratory tests outside the body, supplementation with plasminogen or a2AP inhibition reversed fibrinolysis resistance from Grade 3 to Grade 1. Modelling then suggested absolute mortality reductions of 32 to 36% in patients with Grade 3 resistance if treated with plasminogen or a2AP inhibition. Those modelled reductions are not trial results, but they give a trial a specific target: the most resistant patients, rather than sepsis patients in general. This is the difference between a biomarker that merely predicts death and a biomarker that defines a treatable subgroup, and the preprint earns attention because it tries to make that second move, from association to a candidate intervention in the highest grade. m:…1270

The same logic at birth

A prospective cohort study in Mwanza City, Tanzania, applies the same early-reading logic to newborns. Maternal vaginal pathogenic bacterial colonisation was the strongest independent predictor of early-onset neonatal sepsis in that cohort, while maternal HIV infection and malaria were independently associated with increased hazard, with adjusted hazard ratios of 1.76 and 2.74 respectively. Escherichia coli accounted for 58.3% of culture-confirmed early-onset neonatal sepsis cases in the study population. The implication is that a substantial share of newborn sepsis risk is visible before birth, in maternal infection status, rather than only after a newborn becomes ill. m:…5214

Read together, the two settings point to a shift in how sepsis work should be organised. In intensive care, the useful question may be which patients have blocked fibrinolysis and how that blockade changes over days, not simply whether sepsis is present. In maternity care in high-burden settings, the useful question may be which mothers carry pathogenic colonisation, HIV or malaria, so newborn surveillance can be concentrated where risk is highest. Both approaches replace a general alarm with a measurable profile, and both still need prospective testing before they change care. The shared discipline is to spend monitoring and prevention effort where measured risk is highest, rather than spreading the same effort evenly across all patients and hoping the highest-risk cases are covered. m:…1252 m:…1270 m:…5214

What remains unproven

The intensive care findings are observational and modelled, not evidence from a randomised trial of plasminogen or a2AP inhibition, and the modelled mortality reductions assume treatment works as the laboratory reversal suggests. The Tanzanian findings come from one city cohort, so the relative weight of colonisation, HIV and malaria may differ elsewhere. The honest next step is a trial in the Grade 3 group and stronger maternal screening and newborn surveillance in settings like Mwanza, with results judged on deaths prevented, not on whether a biomarker moved. m:…1270 m:…5214